Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992;34(5):337-42.
doi: 10.1007/BF01741555.

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study

S H Lim  1 , A C Newland, S Kelsey, A Bell, E Offerman, C Rist, D Gozzard, D Bareford, M P Smith, A H Goldstone
Affiliations
Clinical Trial

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study

S H Lim et al. Cancer Immunol Immunother. 1992.

Abstract

A group of 13 patients with acute myeloid leukaemia of differing disease status were treated with continuous intravenous infusion of high-dose recombinant interleukin-2 (rIL-2). There was up-regulation of the cellular cytotoxic functions in all these patients following the rIL-2 therapy, with increase in the natural killer (NK) activity, lectin-dependent cellular cytotoxicity, induction of cytotoxicity-linked cytoplasmic serine esterase and lymphocyte activation. However, the clinical response to rIL-2 in these patients was disappointing, especially in patients treated in frank relapse. Although 1 patient treated in early second relapse achieved a third complete remission, the duration of the remission was brief and lasted only 6 months. Adverse reactions among these patients were common. Whether or not lymphokine-activated killer cells are needed to improve the response rate over rIL-2 alone in these patients deserves further investigation.

PubMed Disclaimer

References

    1. Adler A, Chervenick IA, Whiteside T, Lotzova E, Herberman RB. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood. 1988;71:709–716. - PubMed
    1. Barrett AJ (1989) IL-2 in treatment of haematological malignancies. Presented at the Grantholder's meeting, Leukaemia Research Fund, London, November 1989
    1. Beran M, Hansson M, Kiessling R. Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells. Blood. 1983;61:596–599. - PubMed
    1. Champlin RE, Ho WG, Gale RP, et al. Treatment of acute myelogenous leukemia: a prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med. 1985;102:285–291. - PubMed
    1. Fletcher M, Goldstone AL. Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2. Lymphokine Res. 1987;6:45–57. - PubMed

Publication types

MeSH terms

LinkOut - more resources